共 50 条
Spine Bone Texture Assessed by Trabecular Bone Score (TBS) to Evaluate Bone Health in Thalassemia Major
被引:35
|作者:
Baldini, M.
[1
]
Ulivieri, F. M.
[2
]
Forti, S.
[3
]
Serafino, S.
[4
]
Seghezzi, S.
[4
]
Marcon, A.
[1
]
Giarda, F.
[4
]
Messina, C.
[4
]
Cassinerio, E.
[1
]
Aubry-Rozier, B.
[5
]
Hans, D.
[5
]
Cappellini, M. D.
[1
,4
]
机构:
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Med & Med Special, Rare Dis Ctr, Milan, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Bone Metab Unit, Dept Nucl Med, Milan, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Audiol Unit, Milan, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[5] Lausanne Univ Hosp CHUV DAL, Ctr Bone Dis, Lausanne, Switzerland
关键词:
Thalassemia major;
Osteoporosis;
Trabecular bone score;
BETA-THALASSEMIA;
MINERAL DENSITY;
OSTEOPOROSIS;
MICROARCHITECTURE;
DISEASE;
DXA;
D O I:
10.1007/s00223-014-9919-7
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Due to the increasing survival of thalassemic patients, osteopathy is a mounting clinical problem. Low bone mass alone cannot account for the high fracture risk described; impaired bone quality has been speculated but so far it cannot be demonstrated noninvasively. We studied bone quality in thalassemia major using trabecular bone score (TBS), a novel texture measurement extracted from spine dual-energy X-ray absorptiometry (DXA), proposed in postmenopausal and secondary osteoporosis as an indirect index of microarchitecture. TBS was evaluated in 124 adult thalassemics (age range 19-56 years), followed-up with optimal transfusional and therapeutical regimens, and in 65 non-thalassemic patients (22-52 years) undergoing DXA for different bone diseases. TBS was lower in thalassemic patients (1.04 +/- A 0.12 [range 0.80-1.30]) versus controls (1.34 +/- A 0.11 [1.06-1.52]) (p < 0.001), and correlated with BMD. TBS and BMD values correlated with age, indicating that thalassemia negatively affects both bone quality and quantity, especially as the patient gets older. TBS was 1.02 +/- A 0.11 [0.80-1.28] in the osteoporotic thalassemic patients, 1.08 +/- A 0.12 [0.82-1.30] in the osteopenic ones and 1.15 +/- A 0.10 [0.96-1.26] in those with normal BMD. No gender differences were found (males: 1.02 +/- A 0.13 [0.80-1.30], females 1.05 +/- A 0.11 [0.80-1.30]), nor between patients with and without endocrine-metabolic disorders affecting bone metabolism. Our findings from a large population with thalassemia major show that TBS is a valuable tool to assess noninvasively bone quality, and it may be related to fragility fracture risk in thalassemic osteopathy.
引用
收藏
页码:540 / 546
页数:7
相关论文